What is the use of emrtricitabine and tenofoviru?

Emthricitabine and Tenofovir are antiretroviral drugs used to treat HIV/AIDS in combination with other antiretroviroles. They are often combined in a single preparation and can also be combined with a third medicine such as Epavirenz. Different combinations are known under different trade names by country and manufacturer. In most countries, antiretroviroles are only available on prescription because they require careful choice and monitoring of treatment. Transferred with body fluids is incurable, so prevention is vital. Transmission occurs most often through sexual contact, but can be transmitted by other methods, including the mother to the child during pregnancy and sharing needles, which is a common practice between drug addicts. The virus is quickly multiplied in the body, causing a decrease in immunity. HIV treatment is administered to decelerate the replication of the virus and the time of treatment is usually determined by monitoring the number of CD4, which is a sign of immune condition. The aim of HIV treatment is to reduce HIV viral load to lower than detectiontonname levels.

Emthricitabine and Tenofovir have an imitation of a substrate for reverse transcriptases, which is the enzyme needed for HIV to convert RNA into DNA. They imitate its effect and slow the replication of the virus. EmTricitabine and Tenofovir, while both have the same effect, act in slightly different points. Tenofovir is an inhibitor of nucleotide reverse transcriptases and emrtricitabine is an inhibitor of nucleoside reverse transcriptases.

In the treatment of HIV infection, at least three medicines are used in combination to prevent the development of a resistant virus. Emrtricitabine and Tenofovir can be used together with antiretroviral from another class, such as an inhibitor of non -nucleoside reverse transcriptases such as nevirapin or epavirenz or protease inhibitor such as Lopinavir, reinforced by ritonavir. The selection of the combination will be decided by the physician with regard to the clinical history of the patient.

is a novelYet, so that all antiretroviral drugs, including emtricitabine and tenofovirus and any third drug are prescribed, take exactly as prescribed. Due to the constantly replicating nature of HIV, resistance can quickly develop and adhesion is necessary to maintain viral burden. The normal dose of emtricitabine and tenofoviru is 300 mg tenofovir and emtricitabine 200 mg daily. Antiretroviroles can interact with other medicines and may cause adverse effects in some patients. Before starting treatment, they should be discussed with the prescription physician.